Literature DB >> 6478400

Correlation of cell-cycle kinetics, hormone receptors, histopathology, and nodal status in human breast cancer.

R E Moran, M M Black, L Alpert, M J Straus.   

Abstract

DNA ploidy and percent of (%S-phase) S-phase cells were determined from the DNA content distribution of 21 benign and 76 malignant (69 primary, 7 metastatic) breast tumors using flow cytometry. All of the benign tumors were diploid, whereas 89% of the malignant tumors had measurable aneuploidy. Multiple stem-lines were observed in approximately 10% of the malignant tumors. The ploidy distribution of the malignant tumors was bimodal with an increased frequency of tumors with a near diploid DNA index (DI), and a second group with DI ranging from triploid to tetraploid. The percentage of cells in S-phase ranged from less than 1% to 37.4%. DI and %S were significantly higher in poorly differentiated duct carcinomas, medullary carcinomas, and recurrent tumor metastases. DI and %S were also significantly higher in estrogen-receptor-negative tumors. There was no correlation between DI or %S and the extent of axillary nodal metastases. However, within the groups of node-negative and node-positive patients, DI and %S were not randomly distributed but were significantly correlated with degree of nuclear differentiation. Both parameters were higher in poorly differentiated tumors compared with well-differentiated tumors, indicating significant intrastage heterogeneity in tumor ploidy and proliferation characteristics. Determination of the prognostic significance of DI and %S will require a longer follow-up time.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6478400     DOI: 10.1002/1097-0142(19841015)54:8<1586::aid-cncr2820540820>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Lymph node metastases versus DNA ploidy as prognostic factors for invasive ductal carcinoma of the breast.

Authors:  M Noguchi; T Taniya; N Ohta; N Koyasaki; I Miyazaki; Y Mizukami
Journal:  Breast Cancer Res Treat       Date:  1991-09       Impact factor: 4.872

3.  Flow cytometric DNA hypertetraploidy is associated with unfavourable prognostic features in breast cancer.

Authors:  A E Pinto; S André; M Nogueira; E Mendonça; J Soares
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

Review 4.  Breast cancer in the elderly.

Authors:  M Bellet; C Alonso; B Ojeda
Journal:  Postgrad Med J       Date:  1995-11       Impact factor: 2.401

5.  DNA ploidy level and S-phase fraction as prognostic factors in breast cancer.

Authors:  T Yokoe; M Izuo; T Ishida; Y Iino; T Kawai
Journal:  Jpn J Surg       Date:  1990-09

6.  Nucleolar grading of breast cancer. Comparative studies on frequency and localization of nucleoli and histology, stage, hormonal receptor status and lectin histochemistry.

Authors:  B Helpap
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

7.  Relationship of flow cytometry results to clinical and steroid receptor status in human breast cancer.

Authors:  T E Kute; H B Muss; M Hopkins; R Marshall; D Case; L Kammire
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

8.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

9.  Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.

Authors:  J Harvey; N de Klerk; I Berryman; G Sterrett; M Byrne; J Papadimitriou
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

10.  Determination of growth fractions in benign breast disease (BBD) with monoclonal antibody Ki-67.

Authors:  R J Lellé; W Heidenreich; G Stauch; I Wecke; J Gerdes
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.